AZD6482

Catalog No.S1462 Synonyms: KIN-193

AZD6482 Chemical Structure

Molecular Weight(MW): 408.45

AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

Size Price Stock Quantity  
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Collagen-embedded melanoma spheroids were treated for 72 h with SGI-1776 [5 μM] or AZD6482 [10 μM] as single agents or in combination before staining for live (green) and dead (red) cells. Experiments were conducted in triplicate and representative images are shown. Scale bar represents 150 microns.

    Oncotarget, 2016, 7(34):54897-54912. AZD6482 purchased from Selleck.

    Cells treated with either control or INPP4B siRNA and following a 1-hour treatment with either DMSO or 1 mmol/L inhibitor; pPRAS40T246 and total PRAS40 were run on a separate blot for which the bottom Ku-86 panel is the loading control(pan-PI3Ki: GDC-0941, PI3K-ai: BYL719,PI3K-bi: AZD6482)

    Mol Cancer Res, 2017. AZD6482 purchased from Selleck.

  • Dose response curve of compound on melanoma cell lines.  Compound was dissolved in DMSO, added in a 5-fold dilution series, starting with 10 μM, and incubated for 72 hours.  Fluorescence was measured after 8 hours incubation in resazurin.  Data was normalized to DMSO (maximal viability) and Doxorubicin (minimum viability).

    One customer. AZD6482 purchased from Selleck.

    After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of AZD6482 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. AZD6482 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.
Targets
PI3Kβ [1]
(Cell-free assay)
PI3Kδ [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
PI3Kα [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
10 nM 80 nM 420 nM 870 nM 1090 nM
In vitro

AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human RXF393 cell MnrOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\aWGlvcGmkaYTpc44hd2ZiaIXtZY4hWliIM{mzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTF3NDFOwG0> MWLTRW5ITVJ?
human SW982 cell M33yWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYLJTY41UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODN3OESg{txO M3LOdXNCVkeHUh?=
human MAD-MB-468 cells MnfMSpVv[3Srb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKFCLM1vi[ZRiKGmwIHj1cYFvKE2DRD3NRk01PjhiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBU\XJ2N{OgRYt1KHCqb4PwbI9zgWyjdHnvckBjgSClZXzseYxieiCyb4TlcoN6KGG|c3H5MEBKSzVyPUCuNFQh|ryP MkSyNlQ6QTJ6N{S=
human KURAMOCHI cell NFjKUZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVX5VW5RUW6qaXLpeIlwdiCxZjDoeY1idiCNVWLBUW9EUEliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGwOVEh|ryP MX3TRW5ITVJ?
human A498 cell NWDsOJJxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{LrOWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE4QTVizszN MmPzV2FPT0WU
human YT cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmG0TY5pcWKrdHnvckBw\iCqdX3hckB[XCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUKwOlYh|ryP MWTTRW5ITVJ?
human VMRC-RCZ cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{HCdmlvcGmkaYTpc44hd2ZiaIXtZY4hXk2UQz3SR3oh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2OEm4JO69VQ>? MmTVV2FPT0WU
human MDA-MB-415 cell NUHwPIlLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20NVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4N{OyJO69VQ>? MXHTRW5ITVJ?
human J82 cell NH[2VmxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\mTY5pcWKrdHnvckBw\iCqdX3hckBLQDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS3O|c6KM7:TR?= M33jXnNCVkeHUh?=
human SW1710 cell Mmi4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVI6OiEQvF2= NGLyfYRUSU6JRWK=
human T47D cell NITUVZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\afJpKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{OjdizszN MVzTRW5ITVJ?
human SU-DHL-1 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXPlelE1UW6qaXLpeIlwdiCxZjDoeY1idiCVVT3ETGwuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNU[4NVMh|ryP MYPTRW5ITVJ?
human BT-20 cell Mmf4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3;CSWlvcGmkaYTpc44hd2ZiaIXtZY4hSlRvMkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6OjJ{IN88US=> M1W4RXNCVkeHUh?=
human OS-RC-2 cell NXqy[oVVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlfXTY5pcWKrdHnvckBw\iCqdX3hckBQWy2UQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43OjN6ODFOwG0> MYrTRW5ITVJ?
human RPMI-6666 cell NWHOR2pPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1\tZmlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST22OlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC54NEO3PUDPxE1? NGr6WWJUSU6JRWK=
human OVCAR-3 cell NF;seJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mm\QTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43Pzl2NjFOwG0> MYHTRW5ITVJ?
human NALM-6 cell NVfHXWp7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnvJTY5pcWKrdHnvckBw\iCqdX3hckBPSUyPLU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcxPDZ3IN88US=> MkjkV2FPT0WU
human RS4-11 cell M4e5dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NID4TZZKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzN6ME[g{txO NGm1e4tUSU6JRWK=
human SK-MES-1 cell NVTZNnJYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF75NG1KdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OEm2O{DPxE1? MVPTRW5ITVJ?
human ES7 cell MorkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEGyPFYh|ryP NXTNTINIW0GQR1XS
human NCI-H2342 cell Ml7QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWT6OnVCUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0Nlk1KM7:TR?= M4TQfnNCVkeHUh?=
human SCC-9 cell NUDzUGpxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3H1fWlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg2PzdizszN MUTTRW5ITVJ?
human EW-7 cell NXXPcJViT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki2N|U3KM7:TR?= MkT2V2FPT0WU
human HH cell NVTyUodYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57NkKyNkDPxE1? MV7TRW5ITVJ?
human A427 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGq1dI5KdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk6PTB3IN88US=> MkL6V2FPT0WU
human Daudi cell MojJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2H1b2lvcGmkaYTpc44hd2ZiaIXtZY4hTGG3ZHmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA3QDh6IN88US=> M3nNb3NCVkeHUh?=
human P30-OHK cell M1fZVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV7wOHdOUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yN{GzPEDPxE1? MUHTRW5ITVJ?
human HGC-27 cell M4q4TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoPCTY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVEvOThzNjFOwG0> M1nIWHNCVkeHUh?=
human CAMA-1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVUFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlAxOSEQvF2= NEXEN|VUSU6JRWK=
human SK-OV-3 cell M{WyWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUeye5d[UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{MES0OEDPxE1? NFnOTYpUSU6JRWK=
human NCI-H1048 cell NGTBfGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH6xXpFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMkK1O|kh|ryP MYjTRW5ITVJ?
human MEL-HO cell MonZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jkVGlvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPDJ|ODFOwG0> NG\6cpFUSU6JRWK=
human NKM-1 cell NVLXUnZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3W4SWlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI5PjN4IN88US=> M{Dt[XNCVkeHUh?=
human NCI-H650 cel NXXJNndST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7zTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzByN{[g{txO MUnTRW5ITVJ?
human HAL-01 cell M2rae2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYLyOWtVUW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyMUe1JO69VQ>? MW\TRW5ITVJ?
human 786-0 cell MmTYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fZT2lvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMyOjh|IN88US=> NGj3bodUSU6JRWK=
human GI-1 cell NIPCe2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjtTY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNVgxQCEQvF2= NYjkRY9LW0GQR1XS
human Becker cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXjVelN7UW6qaXLpeIlwdiCxZjDoeY1idiCEZXPr[ZIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN4M{G1JO69VQ>? M2C4b3NCVkeHUh?=
human CCF-STTG1 cell NVLMUZFnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LmOmlvcGmkaYTpc44hd2ZiaIXtZY4hS0OILWPUWGcyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52MkWyOUDPxE1? NF3mOVdUSU6JRWK=
human MC116 cell NXjKd|R3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWW5OWxRUW6qaXLpeIlwdiCxZjDoeY1idiCPQ{GxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDZzMkKg{txO MoS1V2FPT0WU
human MDA-MB-468 cell M4npU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\ZTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtOFY5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53M{ezOkDPxE1? MXXTRW5ITVJ?
human NB12 cell NHT0fnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnXDTY5pcWKrdHnvckBw\iCqdX3hckBPSjF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61OFg1OiEQvF2= NFjOPIFUSU6JRWK=
human LXF-289 cell NFj6UI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVnWNZlMUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53NUGwOEDPxE1? NFXSNpdUSU6JRWK=
human MFE-296 cell NEjqc2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\te3pKdmirYnn0bY9vKG:oIHj1cYFvKE2IRT2yPVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV4OEO2JO69VQ>? NHnYT4JUSU6JRWK=
human SNU-423 cell M3e5TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS12MkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4OTl{IN88US=> MlniV2FPT0WU
human NCI-H2291 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIjPfVRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlI6OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNUe2NUDPxE1? NYHPcpc1W0GQR1XS
human OCUB-M cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGn2fmNKdmirYnn0bY9vKG:oIHj1cYFvKE:FVVKtUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTh|MUSg{txO MUTTRW5ITVJ?
human KU812 cell NFTvNWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mk\mTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVk3OjhizszN NYLycJUxW0GQR1XS
human HuO9 cell NHLpcoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH3uNnpKdmirYnn0bY9vKG:oIHj1cYFvKEi3T{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyOjhizszN NG\6NXRUSU6JRWK=
human 639-V cell M1:2fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJFY{QS2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62N|E1PCEQvF2= NFy1SFNUSU6JRWK=
human HCC70 cell NGTVXHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2W4bmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFN{CgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY3OTR4IN88US=> M2WxbXNCVkeHUh?=
human SNB75 cell MkjnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIjrRolKdmirYnn0bY9vKG:oIHj1cYFvKFOQQke1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PjVyODFOwG0> MX\TRW5ITVJ?
human D-336MG cell NGPCeGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MorMTY5pcWKrdHnvckBw\iCqdX3hckBFNTN|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Pjh6IN88US=> MXzTRW5ITVJ?
human LoVo cell NIDMRphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn;JTY5pcWKrdHnvckBw\iCqdX3hckBNd1[xIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63N|gzPSEQvF2= NImzXHhUSU6JRWK=
human EB2 cell NH;IN4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;0T2lvcGmkaYTpc44hd2ZiaIXtZY4hTUJ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63OVAyQSEQvF2= M1H5S3NCVkeHUh?=
human HSC-2 cell NIrmO3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHPv[W9KdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PTd{NzFOwG0> MmLzV2FPT0WU
human D-542MG cell MoLoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7jfINKdmirYnn0bY9vKG:oIHj1cYFvKERvNUSyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh3MEe3JO69VQ>? M3SzeXNCVkeHUh?=
human COLO-684 cell NF7PbJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml;uTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjByM{Kg{txO M33C[3NCVkeHUh?=
human GDM-1 cell NHnPdWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HmbmlvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI1OjB4IN88US=> M3[zfnNCVkeHUh?=
human SW1088 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3i3R2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41QDF2MzFOwG0> MYHTRW5ITVJ?
human SF295 cell NGPHUG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIq5SWpKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44Pjl3NTFOwG0> NUTqRoNwW0GQR1XS
human NCI-H2030 cell MkW2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIr3[3RKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUCyPFgh|ryP MUPTRW5ITVJ?
human NCI-H1755 cell M1PWbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlTVTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ5ME[zJO69VQ>? NF\mTVdUSU6JRWK=
human MDA-MB-361 cell M4PGRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV{N{C5JO69VQ>? MUXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:[1]
+ Expand

Assay of PI3K enzyme inhibition:

The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
Cell Research:[1]
+ Expand
  • Cell lines: Human platelet pellet
  • Concentrations: 0–60 nM, dissolved in DMSO
  • Incubation Time: 5 min
  • Method: For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 1015/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.75 mM)
Ethanol 10 mg/mL (24.48 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.45
Formula

C22H24N4O4

CAS No. 1173900-33-8
Storage powder
Synonyms KIN-193

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00853450 Completed Antiplatelet Effect AstraZeneca February 2009 Phase 1
NCT00688714 Completed Antiplatelet Effect AstraZeneca January 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy AZD6482 | AZD6482 supplier | purchase AZD6482 | AZD6482 cost | AZD6482 manufacturer | order AZD6482 | AZD6482 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID